On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details
FridayDec 09, 2016 2:00 pm

NetworkNewsBreaks – Long Island Iced Tea Corp. (LTEA) Inks First Acquisition Deal; Shares Tick Higher

Long Island Iced Tea Corp. (NASDAQ: LTEA) this morning said it will acquire the ALO Juice® beverage brand and trademark rights from The Wilnah International, LLC for a purchase price of 5,000 shares of the company's common stock. The company has been distributing ALO Juice® since February 2016, with nearly $1 million worth sold to date. The closing of the transaction is anticipated for the first quarter of 2017, subject to customary conditions. "ALO Juice® is a quality brand. We are excited that it will mark the first brand acquisition in our five-year history," Long Island Iced Tea CEO Philip…

Continue Reading

ThursdayDec 08, 2016 1:59 pm

NetworkNewsBreaks – Anavex Life Sciences (AVXL) Releases Positive Data for ANAVEX 2-73 in Alzheimer’s Study; Trading Higher

Shares of Anavex Life Sciences (NASDAQ: AVXL) are higher after the company said its ANAVEX 2-73 candidate met primary and secondary endpoints in a phase 2a study of patients with mild-to-moderate Alzheimer’s disease (AD). ANAVEX 2-73 was well tolerated and there were no clinically significant treatment-related adverse events and no serious adverse events. Despite non-optimized dosing of ANAVEX 2-73 throughout the 12-month study, continued significant improvements from baseline of cognitive, functional and behavioral scores in a group of patients were observed, respectively. "We believe this data gives us a solid foundation from which to continue the next phase of rationally…

Continue Reading

WednesdayDec 07, 2016 1:02 pm

NetworkNewsBreaks – Broadwind Energy (BWEN) Receives New Tower Orders Valued at $23M

Broadwind Energy (NASDAQ: BWEN) this morning said it recently received $23 million in new tower orders for 2017 delivery. The company will produce these towers in its Manitowoc, Wisconsin, and Abilene, Texas, facilities. “We have booked over $250 million in new tower orders so far in 2016.  Both of our tower manufacturing facilities are operating consistently and a good portion of our 2017 capacity is under contract. We are proud of the contributions our highly-skilled team is making to U.S. manufacturing and to the wind industry,” Stephanie Kushner, president and CEO of Broadwind, stated in the news release. To view…

Continue Reading

WednesdayDec 07, 2016 1:00 pm

NetworkNewsBreaks – Bridgeline Digital (BLIN) Trading Higher on $1.5M Deal with Global Engines Manufacturer

Bridgeline Digital (NASDAQ: BLIN) released news this morning that its iAPPS platform has been selected to power one of the world’s largest engine manufacturers’ eCommerce website in a deal expected to total more than $1.5 million in iAPPS licenses, hosting and associated professional services. In making its selection, the engine manufacturer noted iAPPS’s ability for simple globalization, multi-site management and intuitive digital marketing capabilities. “This company needed a system that took care of all of the basics when it came to their online commerce presence, while layering on the necessary personalization and digital marketing functionality to drive engagement and conversions.…

Continue Reading

MondayDec 05, 2016 4:00 pm

NetworkNewsBreaks – EyeGate (EYEG) Announces Positive Data from Third Stage of Phase Ib/IIa Clinical Trial of EGP-437

EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) today reported promising data from the third stage of its phase Ib/IIa trial assessing iontophoretic EGP-437 for the treatment of ocular inflammation and pain in post-surgical cataract patients. Consistent with the first two stages of the trial, the procedure was very well tolerated in all subjects. Stage three of this multi-center, open-label clinical trial enrolled 30 subjects who have undergone cataract surgery with implantation of a posterior chamber intraocular lens (“IOL”). Patients were divided into three groups receiving iontophoretic doses of EGP-437 at either 4.5 mA-min or 14.0 mA-min, or a placebo at 14.0 mA-min.…

Continue Reading

MondayDec 05, 2016 3:58 pm

NetworkNewsBreaks – Ocean Power Technologies (OPTT) Signs Joint Marketing Agreement with Sonalysts

In a news release issued earlier today, Ocean Power Technologies, Inc. (NASDAQ: OPTT) and Sonalysts, Inc. announced their entry into a joint marketing agreement in defense and oil and gas applications where persistent power, real-time data collection, processing, and transmission are critical. OPTT’s PB3 PowerBuoy® is a power and communication platform for remote offshore applications that enables the use of advanced multi-functional sensors and autonomous underwater vehicles. Sonalysts maintains core technology in undersea wireless communications and in autonomous undersea systems analysis, which are available to a variety of commercial and defense customers such as the U.S. Navy Submarine Force. “We…

Continue Reading

MondayDec 05, 2016 3:54 pm

NetworkNewsBreaks – Cerecor (CERC) Phase 2 Study Top-Line Results of CERC-501 Display Favorable Side-Effect Profile

Cerecor Inc. (NASDAQ: CERC) announced top-line clinical results from its nicotine withdrawal phase 2 clinical trial of CERC-501 today. Although the trial did not meet its primary objective in nicotine withdrawal, the oral, potent, and selective kappa opioid receptor ("KOR") antagonist was well tolerated with no serious adverse events reported and no discontinuations due to adverse events. Based on this favorable side-effect profile, the company intends to move forward with its previously planned development of CERC-501 in its primary indication, as an adjunctive treatment of Major Depressive Disorder (MDD). "There is preclinical and recent clinical evidence that strongly support the potential…

Continue Reading

FridayDec 02, 2016 1:51 pm

NetworkNewsBreaks – Skyline Medical (SKLN) Names Dr. Carl Schwartz Chief Executive Officer, Expands Board of Directors

Skyline Medical (NASDAQ: SKLN) this morning named Dr. Carl Schwartz as the company’s newly appointed chief executive officer. Dr. Schwartz is a longtime stockholder of Skyline, for which he has served as a director, interim CEO and executive chairman. He holds BA and DDS degrees from the University of Detroit. The company also announced that Richard Gabriel has been appointed to its board of directors, bringing the number of directors to six. Both appointments are effective immediately. To view the full press release, visit: http://nnw.fm/jwBp1 About Skyline Medical Skyline Medical produces a fully automated, patented, FDA-cleared waste fluid disposal system…

Continue Reading

FridayDec 02, 2016 1:50 pm

NetworkNewsBreaks – Boston Scientific (BSX) Acquires Certain Neovasc (NVCN) Assets for $75M, Commits to Equity Interest

Earlier this morning, Neovasc (NASDAQ: NVCN) announced an agreement with long-term customer Boston Scientific (NYSE: BSX), pushing shares of Neovasc nearly 50% higher. Per the agreement, Boston Scientific will acquire Neovasc's tissue processing technology and facility for approximately $67.9 million in a deal expected to close by year-end 2016. Neovasc has been granted a license to the purchased assets and access to the sold facilities, which will allow the company to continue its tissue and valve assembly for its remaining customers, as well as its own tissue-related programs. Boston Scientific has also committed to purchasing 11,817,000 common shares at a…

Continue Reading

ThursdayDec 01, 2016 3:25 pm

NetworkNewsBreaks – Biostage (BSTG) Shares Soar after FDA Grants Cellspan™ Esophageal Implant Orphan Drug Designation

Biostage, Inc. (NASDAQ: BSTG) is trading 30% higher following news that the company’s Cellspan™ Esophageal Implant was granted Orphan Drug Designation to restore the structure and function of the esophagus subsequent to esophageal damage due to cancer, injury or congenital abnormalities. This designation provides for a seven-year marketing exclusivity period against competition upon marketing approval, as well as certain incentives, including tax credits and a waiver of PDUFA filing fees. Biostage said it expects to file its IND in the third quarter of 2017 followed by its phase 1 first-in-human clinical study in the fourth quarter of 2017. "We believe…

Continue Reading

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217